高尿酸血症对FUTURE 2-5和MAXIMISE研究中接受司库奇尤单抗治疗的银屑病关节炎患者的影响
该事后汇总分析基于FUTURE 2-5和MAXIMISE研究,以基线血尿酸360 µmol/L为阈值将银屑病关节炎患者分为高尿酸血症与尿酸正常两组,并另以300 µmol/L和420 µmol/L做敏感性分析。结果显示高尿酸血症组更多为男性、高血压患病率更高、指炎和银屑病更多且皮肤病变更重,但各司库奇尤单抗剂量下第52周的ACR应答、附着点炎和指炎消退、结构损伤进展抑制及健康相关生活质量改善在两组间比例相似。
要点
- 以基线血尿酸360 µmol/L为阈值分层,高尿酸血症组更多为男性、高血压更多、指炎和银屑病更多且皮肤病变更重。
- 各司库奇尤单抗剂量下第52周,尿酸正常与高尿酸血症两组达到ACR应答、附着点炎和指炎消退、结构损伤进展抑制及生活质量改善的比例相似。
- 作者认为早期识别高尿酸血症患者可能有助于个体化治疗和改善合并症管理,司库奇尤单抗对银屑病关节炎各表现的应答不受基线尿酸状态影响。
核心结论
- 伴高尿酸血症的银屑病关节炎患者与尿酸正常患者临床特征不同。
- 司库奇尤单抗至第52周对银屑病关节炎各表现均提供快速且持续的应答,与基线尿酸状态无关。
- 作者认为早期识别这些患者可能有助于个体化治疗和改善合并症管理。
研究设计与样本
- 基于FUTURE 2-5研究和MAXIMISE研究的汇总数据进行的全面事后分析。
- 按基线血尿酸水平360 µmol/L为阈值将患者分为高尿酸血症组和尿酸正常组,并以300 µmol/L和420 µmol/L为阈值进行敏感性分析。
- 收集人口学、临床、影像学特征和合并症数据。
主要发现
- 基线时高尿酸血症组更多为男性,高血压患病率更高,临床指炎更多,银屑病更多且皮肤病变更严重,与尿酸正常组相比。
- 在各司库奇尤单抗剂量下第52周,尿酸正常组与高尿酸血症组达到ACR应答、附着点炎和指炎消退、结构损伤进展抑制及健康相关生活质量改善的患者比例相似。
关键数值与推荐
- 基线血尿酸分层阈值为360 µmol/L,敏感性分析阈值为300 µmol/L和420 µmol/L。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with psoriatic arthritis (PsA) are at a significantly increased risk of hyperuricaemia and development of gout, and those with hyperuricaemia have been found to respond poorly to PsA treatment and have more peripheral and destructive joint damage. We present a comprehensive post hoc analysis using pooled data from the FUTURE 2-5 studies and the MAXIMISE study to further evaluate the impact of hyperuricaemia on clinical presentation/disease severity and response to secukinumab in patients with PsA. METHODS: Patients were stratified into two groups based on baseline serum uric acid (SUA) level (threshold of 360 µmol/L). A sensitivity analysis was also performed based on SUA thresholds of 300 µmol/L and 420 µmol/L. Demographics, clinical, radiological characteristics and comorbidities data were collected. RESULTS: At baseline, patients with hyperuricaemia were mostly male, reported a higher prevalence of hypertension, with more clinical dactylitis, more psoriasis and more severe skin disease compared with patients with normouricaemia. A similar proportion of patients in the normouricaemic and hyperuricaemic cohorts achieved American College of Rheumatology responses, resolution of enthesitis and dactylitis, inhibition of structural damage progression and improvement in health-related quality of life across all secukinumab doses at week 52. CONCLUSION: Patients with PsA and hyperuricaemia have different clinical characteristics from patients with PsA and normouricaemia. Identification of these patients at an early stage may facilitate a personalised treatment approach and improved management of comorbidities. Furthermore, secukinumab provided a rapid and sustained response across all manifestations of PsA up to week 52, irrespective of baseline uricaemia status.
引用
- Felten R, Widawski L, Spielmann L, et al. Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies. RMD Open. 2023. PMID: 37945285. doi:10.1136/rmdopen-2023-003428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。